Halozyme Therapeutics (NASDAQ:HALO) Reaches New 12-Month High – Still a Buy?

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) reached a new 52-week high during mid-day trading on Tuesday. The company traded as high as $128.35 and last traded at $127.55, with a volume of 58,059 shares. The stock had previously closed at $128.01.

Analyst Upgrades and Downgrades

Several research firms have weighed in on HALO. Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. HC Wainwright increased their target price on Halozyme Therapeutics from $115.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, October 7th. Weiss Ratings upgraded Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, August 31st. Wall Street Zen upgraded Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Finally, Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $99.55.

Halozyme Therapeutics Stock Up 1.2%

The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The company’s fifty day moving average price is $112.74 and its 200-day moving average price is $82.87. The stock has a market capitalization of $14.76 billion, a PE ratio of 38.82, a price-to-earnings-growth ratio of 0.47 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The company had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. During the same quarter in the prior year, the business posted $1.54 EPS. The firm’s quarterly revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Analysts forecast that Halozyme Therapeutics, Inc. will post 8.31 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Matthew Posard sold 5,230 shares of the stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $108.54, for a total value of $567,664.20. Following the sale, the director directly owned 53,609 shares of the company’s stock, valued at approximately $5,818,720.86. This represents a 8.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the sale, the director directly owned 40,418 shares in the company, valued at approximately $4,154,970.40. This represents a 3.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 125,852 shares of company stock valued at $13,538,046. 2.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of hedge funds have recently bought and sold shares of HALO. Horizon Investment Services LLC purchased a new position in shares of Halozyme Therapeutics in the second quarter worth approximately $2,254,000. WINTON GROUP Ltd grew its position in Halozyme Therapeutics by 704.6% during the second quarter. WINTON GROUP Ltd now owns 60,348 shares of the biopharmaceutical company’s stock valued at $4,723,000 after buying an additional 52,848 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Halozyme Therapeutics in the second quarter worth approximately $1,025,000. Great Lakes Advisors LLC bought a new position in Halozyme Therapeutics in the second quarter worth approximately $2,821,000. Finally, Chase Investment Counsel Corp purchased a new position in shares of Halozyme Therapeutics during the 2nd quarter worth $2,035,000. Institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.